Should the new EASL–EASD–EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0168-8278
-
Container-title:Journal of Hepatology
-
language:en
-
Short-container-title:Journal of Hepatology
Author:
Silva Júnior Wellington S.ORCID,
Sposito Andrei C.ORCID,
Godoy-Matos AmélioORCID
Reference12 articles.
1. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);J Hepatol,2024
2. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes;Godoy-Matos;Diabetol Metab Syndr,2024
3. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
4. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study;Armstrong;Lancet,2016
5. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis;Newsome;N Engl J Med,2021